Mounjaro vs Ozempic Price: What Actually Applies in the UK

If you are searching for mounjaro vs ozempic price, the first thing to know is that this page does not publish prices for prescription-only medicines such as Mounjaro or Ozempic, and a simple price comparison is often misleading because costs can vary with dose escalation and any prescribing or service fees. 

This comparison appears constantly online, and most of it is written for the United States, where the licensing position is different. In the UK it does not work, for a straightforward reason.

Ozempic is licensed here for type 2 diabetes. It is not a licensed weight loss treatment. The semaglutide product licensed for weight management in the UK is Wegovy, which contains the same active substance at different doses.

So the comparison people are usually reaching for, which is between two weight management options, is Wegovy and Mounjaro rather than Ozempic and Mounjaro.

For UK adults considering or using prescription treatment for type 2 diabetes or weight management, that distinction affects more than labels: it shapes safe prescribing, access, national supply pressures, and whether treatment follows UK guidance.

This page sets out what each medicine is licensed for, how Ozempic, Mounjaro and Wegovy differ in approved use and clinical position, the issues around off-label prescribing, current UK safety and supply alerts, and where cost fits into the decision without letting cost alone drive a choice between licensed and unlicensed use.

Key things to know

• Ozempic contains semaglutide and is licensed in the UK for type 2 diabetes.
• Wegovy contains the same active substance and is licensed for weight management.
• Mounjaro contains tirzepatide and is licensed for both weight management and type 2 diabetes.
• UK health authorities have previously strongly discouraged off-label use of certain GLP-1 medicines for obesity, particularly during periods of constrained supply.
• That position followed national supply shortages driven partly by off-label demand.
• If you want a semaglutide treatment for weight management, the licensed route is Wegovy.
• We do not publish prices for prescription-only medicines.

The licensing position

Marketing authorisation and NHS access are not the same thing. A medicine may be licensed for a particular use while NHS prescribing is subject to additional NICE recommendations, commissioning arrangements and eligibility criteria.

Why Ozempic is not a weight loss medicine here

What off-label use means

Off-label prescribing means a medicine is used outside its authorised indication. It is not automatically illegal or inappropriate, and UK prescribers may do it where they judge it clinically justified, taking additional responsibility for that decision.

What makes this case different is that there is a licensed alternative containing the same active substance, and there is a national position discouraging off-label use. NHS access can be more restrictive than the medicine's marketing authorisation because NICE recommendations and local or national commissioning arrangements may set additional eligibility criteria. Private prescribing is also subject to clinical assessment and the medicine's licensed indication or a clinically justified off-label decision.

The national position

In July 2023 the Department of Health and Social Care issued a National Patient Safety Alert covering GLP-1 receptor agonists, following national supply shortages caused by increased demand for both licensed and off-label use.

The alert stated that Ozempic is indicated for adults with insufficiently controlled type 2 diabetes, that off-label use of these medicines for the management of obesity is strongly discouraged, and that stock must be conserved for people with type 2 diabetes.

The practical reason was straightforward. People who needed these medicines to manage diabetes were struggling to obtain them, in part because of demand from people seeking them for weight loss.

Why this still matters

Supply has improved since then, but the licensing position has not changed, and neither has the principle behind the alert.

If you want a semaglutide treatment for weight management, Wegovy is the licensed route and prescribing depends on eligibility criteria such as body mass index; in the relevant weight-management pathway.

Mounjaro is licensed for weight management in adults with a BMI of 30 or more, or a BMI of 27 to under 30 with at least one weight-related comorbidity. NHS prescribing may be subject to additional NICE and commissioning criteria.

There is no clinical advantage to pursuing the unlicensed route, and a prescriber supplying Ozempic for weight loss is making an off-label decision they would need to justify.

The comparison that does apply

If you are weighing up weight-loss treatment options in the UK, the licensed injectable options include Wegovy and Mounjaro.

They differ in mechanism. Mounjaro contains tirzepatide, which acts on both the GLP-1 and GIP receptors, while semaglutide acts on the GLP-1 receptor. Both are licensed for weight management within defined BMI criteria, but NHS eligibility can differ because NICE recommendations and commissioning arrangements apply

We cover that comparison, the trial findings and the eligibility criteria on separate pages, since those are the questions people are actually asking when they search for this one.

If you are already taking Ozempic

For type 2 diabetes

Then you are taking it for its licensed indication and nothing here suggests otherwise. Continue as prescribed and raise any questions with your prescriber or pharmacist.

If you are also interested in weight management, that is a conversation with your prescriber rather than a reason to change anything yourself.

Obtained for weight loss

If you have been supplied Ozempic for weight management, speak to a prescriber rather than simply stopping.

Things worth establishing:

1. Whether a licensed alternative would be appropriate for you
2. Whether a switch is clinically sensible, and how it would be managed
3. Whether you were assessed properly before supply, including your current medication and other health conditions, before deciding whether a licensed alternative is appropriate
4. Where it came from, and whether that supplier is a registered pharmacy

Do not stop abruptly or switch yourself. The doses are not interchangeable between products, and any switch should be planned with a prescriber.

If you obtained it without a prescription

Tell a clinician what you took and when. Be straightforward about it. They need the information rather than an explanation, and they will have heard it before.

Products supplied outside the regulated system are not covered by MHRA oversight. The MHRA has found illegally supplied weight loss pens containing insulin rather than the labelled medicine, which caused dangerously low blood sugar and hospital admissions in people without diabetes.

On cost

We do not publish prices for prescription-only medicines, and a price comparison would not answer the question anyway.

The more useful exercise is working out the total cost of a full course rather than comparing a first month figure. These treatments involve a dose that builds up in steps, so the monthly amount changes, and consultation, review, delivery and ongoing support may be included or added depending on the service, and insurance coverage can materially change what someone actually pays, which is why list prices and out-of-pocket costs often differ.

One thing is worth saying plainly. Choosing an unlicensed route on cost grounds is not a saving. It means using a medicine outside its authorised indication, without the licensed alternative's product information to rely on, and in a category where supply has previously been constrained for the people who need it most.

What these medicines have in common

Whichever is appropriate for you:

• All three are prescription-only medicines and should be supplied following an appropriate clinical assessment.
• All can reduce appetite and affect gastric emptying, although they work through different receptor pathways and individual responses vary
• The injectable versions discussed here are administered once weekly.
• Gastrointestinal side effects are common with all three medicines, particularly during dose escalation.
• All have important safety information covering gastrointestinal effects and potentially serious adverse reactions, including pancreatitis and dehydration-related kidney problems.
• These medicines are not recommended during pregnancy, and specific advice applies when planning pregnancy or breastfeeding. Anyone who is pregnant, planning pregnancy or breastfeeding should discuss treatment with their prescriber.

Red flags

Seek urgent medical attention for severe and persistent stomach pain that may spread through to your back, with or without nausea and vomiting; swelling of the face, lips, tongue or throat; difficulty breathing; or signs of significant dehydration.

Contact your prescriber if you have been supplied a medicine for an indication you are unsure about, if side effects are not settling, or if you develop symptoms of low blood sugar, particularly if you also use insulin or a sulfonylurea.

The short version

If you came here to work out which of Ozempic and Mounjaro is the licensed weight-management option, the distinction is important: Mounjaro is licensed for weight management, while Ozempic is licensed for type 2 diabetes

That is not a technicality. It determines what product information applies, what your prescriber is responsible for, and whether you are competing for supply with people who need the medicine for a condition it was designed to treat.The safer approach is to use a medicine that is licensed for the indication being treated and to make any treatment decision with an appropriately qualified prescriber.

Medical Disclaimer

This article is for general information only. It is not medical advice and it does not replace the patient information leaflet supplied with your medicine or an individual assessment by an appropriately qualified healthcare professional.

Ozempic, Wegovy and Mounjaro are prescription-only medicines. They should only be used under the supervision of an appropriately qualified prescriber, following a clinical assessment that considers your medical history, current medication, current medicines and other conditions. Treatment suitability depends on an individual clinical assessment, and results vary between individuals.

Do not start, stop, switch or change a prescribed medicine without advice, and do not assume doses are interchangeable between products. Do not obtain prescription medicines outside the regulated system.

Seek urgent medical attention for severe and persistent stomach pain that may spread to your back, swelling of the face, lips, tongue or throat, difficulty breathing, or signs of significant dehydration. Suspected side effects can be reported through the Yellow Card scheme, which the MHRA uses to monitor the safety of medicines.